In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics (NASDAQ: ATOS), with a price target of $10. The company’s shares opened today at $4.10, close to its 52-week low of $2.64.
McCarthy said:
“Atossa reported 1Q18 with a net loss of $1.9M and ended the period with $4.8M in cash. The company is in the process of raising capital which should bring in an additional $20M (factored into our model already, see note from 5/3). Pending completion of the raise, Atossa should have cash runway into 2H19 and through multiple catalysts.”
According to TipRanks.com, McCarthy is a 3-star analyst with an average return of 2.4% and a 40.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.08 and a one-year low of $2.64. Currently, Atossa Genetics has an average volume of 2.3M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.
Read More on ATOS:
